Abstract
Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.
| Original language | English |
|---|---|
| Journal | European Oncology and Haematology |
| Volume | 10 |
| Issue number | 2 |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- AEZS-108
- LHRH
- Relapse
- Targeted
- Urothelial carcinoma
- Zoptarelin doxorubicin
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
Single case of a complete response in a metastatic urothelial carcinoma patient treated with zoptarelin doxorubicin. / Fernandez, Gustavo; Schally, Andrew V; Sengul, Tulay; Jorda, Merce; Merchan, Jaime R; Flores, Aurea M.; Restrepo, Maria H; Block, Norman L.
In: European Oncology and Haematology, Vol. 10, No. 2, 01.01.2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Single case of a complete response in a metastatic urothelial carcinoma patient treated with zoptarelin doxorubicin
AU - Fernandez, Gustavo
AU - Schally, Andrew V
AU - Sengul, Tulay
AU - Jorda, Merce
AU - Merchan, Jaime R
AU - Flores, Aurea M.
AU - Restrepo, Maria H
AU - Block, Norman L
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.
AB - Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.
KW - AEZS-108
KW - LHRH
KW - Relapse
KW - Targeted
KW - Urothelial carcinoma
KW - Zoptarelin doxorubicin
UR - http://www.scopus.com/inward/record.url?scp=84920982730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920982730&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84920982730
VL - 10
JO - European Oncology and Haematology
JF - European Oncology and Haematology
SN - 2045-5275
IS - 2
ER -